Protocol of GLUcose COntrol Safety and Efficacy in type 2 DIabetes, a NETwork meta ‐analysis: GLUCOSE DINET protocol—Rational and design

Abstract The aim of this study was to propose a ranking of the currently available antidiabetic drugs, regarding vascular clinical outcomes, in patients with type 2 diabetes, through a network meta‐analysis approach. Randomized clinical trials, regardless of the blinding design, testing contemporary antidiabetic drugs, and considering clinically relevant outcomes in patients with type 2 diabetes mellitus will be included. The primary outcomes of this analysis will be overall mortality, cardiovascular mortality, and major cardiovascular events. Diabetic microangiopathy will be a secondary outcome. Adverse events, hypoglycemia, weight evolution, bariatric surgery, and discontinuation of the treatment will also be recorded. Each drug will be analyzed according to its therapeutic class: biguanide, alpha‐glucosidase inhibitors, sulfonylureas, glitazones, glinides, insulin, DPP‐4 inhibitors, GLP‐1 analogs, and gliflozins. The treatment effect of each drug class will be compared using pairwise meta‐analysis and a Bayesian random model network meta‐analysis. Sensitivity analyses will be conducted according to the quality of the studies and the glycemic control. The report will follow the PRISMA checklist for network meta‐analysis. Results of the search strategy and of the study selection will be presented in a PRISMA compliant flowchart. The treatment effects will be summarized with odds ratio (OR) estimates and their 95% credible intervals. A ranking of the drugs will ...
Source: Fundamental and Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Review Article Source Type: research